JILIN CHANGLONG (08049) announced its interim results, with profit attributable to shareholders amounting to 123 million yuan, a year-on-year increase of 19.25%.
Jilin Changlong Pharmaceutical (08049) announced its interim results for 2026, reporting a revenue of 436 million yuan, a year-on-year decrease of 0.87%; the profit attributable to shareholders was 123 million yuan, a year-on-year increase of 19.25%; earnings per share were 21.92 cents.
JILIN CHANGLONG (08049) announced its interim results for 2026, achieving a turnover of 436 million yuan, a decrease of 0.87% year-on-year; the profit attributable to shareholders was 123 million yuan, an increase of 19.25% year-on-year; earnings per share were 21.92 cents.
Related Articles
Jinchuan International (02362) announced its interim results, with shareholders' profit attributable to shareholders reaching 47.816 million USD, a year-on-year increase of 766.07%.
CNBM (03323) plans to increase its capital in China National Materials High-Tech.
MIRAMAR HOTEL (00071) announces its interim results, with shareholders' profit attributable to them rising 3.0% year-on-year to HKD 332 million.
Jinchuan International (02362) announced its interim results, with shareholders' profit attributable to shareholders reaching 47.816 million USD, a year-on-year increase of 766.07%.
CNBM (03323) plans to increase its capital in China National Materials High-Tech.
MIRAMAR HOTEL (00071) announces its interim results, with shareholders' profit attributable to them rising 3.0% year-on-year to HKD 332 million.
RECOMMEND
